Stefan Schultz, CEO of Vifor Fresenius, said managing bone and mineral disorders in chronic kidney disease patients “remains a challenge for physicians despite the treatment options already available to them.” He noted that the clinical data for Rayaldee “shows promising safety and efficacy and we strongly believe that once approved, Rayaldee will become a cornerstone therapy to better address this key co-morbidity and improve the well-being of chronic kidney disease patients.”
The estimated value of the markets covered by the incensing agreement is expected to reach about $1 billion in two years, and the U.S. market to exceed $1 billion
I'm would say that Doc took tax implications into consideration also with using Eirgen in Ireland to ink this deal.
VFMCRP would also pay EirGen up to an additional aggregate amount of $555 million upon the achievement of certain milestones and would be obligated to pay certain double digit royalties on VFMCRP’s sales in the United States for the Dialysis Indication.
Sentiment: Strong Buy
Using the debt to pay dividends has a very favorable affect on the tax liabilities I would think. The divvy is why I invested years ago for, the pps appreciation has been wonderful, the 5% bonus in stock shares every year so far is also a big bonus. I agree with juan that a spin off of the real estate portion of the company could also happen and bring more shareholder value.